What patients need to know: What are the efficacy and side effects of dabrafenib?

Dabrafenib is an oral small molecule drug developed for the BRAF V600E mutation target. It is widely used in the treatment of a variety of solid tumors, especially in metastatic melanoma, thyroid cancer, and non-small cell lung cancer. It shows good therapeutic prospects. It selectively inhibits the activity ofBRAF kinase and blocks the MAPK/ERK signaling pathway, thereby inhibiting the proliferation and survival of tumor cells. This precise mechanism makes dabrafenib highly targeted at the molecular level and highly effective, especially for patients with confirmed BRAF mutations.

In clinical use, dabrafenib is usually used in combination withMEK inhibitors such as trametinib to enhance the efficacy and reduce the probability of single-drug resistance. Studies have shown that this combination regimen can significantly extend progression-free survival and overall survival, and the overall safety is controllable.

Although dabrafenib has obvious targeted efficacy, it may also cause some adverse reactions during the treatment process. Common side effects include fever, fatigue, rash, joint pain, headache, loss of appetite, etc. Fever is one of its more characteristic reactions, and some patients even experience repeated episodes of high fever. Skin-related side effects are also more common, such as erythema, dryness, itching, and may even develop into skin tumors or abnormal keratosis, so patients need to undergo regular skin examinations while taking it.

In addition, some patients may experience adverse reactions such as increased liver function indicators, blood sugar fluctuations, or abnormal heart function, which need to be monitored regularly through blood and imaging tests during treatment. Gastrointestinal reactions such as nausea, vomiting, and diarrhea may also occur. It is recommended that patients eat light and easy-to-digest foods and take medicine in small doses in divided doses to alleviate symptoms.

Reference materials:https://go.drugbank.com/drugs/DB08912